FDA grants breakthrough status to uniQure’s Huntington’s disease therapy
The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for Huntington's disease.
The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for Huntington's disease.
What's Your Reaction?
